Analysis reveals low-dose colchicine may benefit patients with atherosclerotic cardiovascular disease, suggesting potential for inflammation-focused treatment strategies.
Cardiovascular disease remains a leading cause of morbidity and mortality worldwide. Though inflammation plays an important role in atherogenesis, treatments directly targeting inflammatory pathways have had mixed results on improving clinical outcomes. Low-dose colchicine has been studied recently for the management of atherosclerotic cardiovascular disease. We explore the history of colchicine as an anti-inflammatory agent, review clinical trial data of colchicine for atherosclerotic cardiovascular disease, and discuss practical considerations for adding low-dose colchicine in this setting.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: